In a filing, Adicet Bio Inc revealed its Director Kauffman Michael unloaded Company’s shares for reported $8437.0 on Jun 05 ’24. In the deal valued at $1.43 per share,5,900 shares were sold. As a result of this transaction, Kauffman Michael now holds 5,900 shares worth roughly $3599.0.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in mid September from “a Buy” to “a Neutral”. JMP Securities also remained covering ACET and has decreased its forecast on June 27, 2023 with a “Mkt perform” recommendation from previously “Mkt outperform” rating. Guggenheim revised its rating on June 27, 2023. It rated ACET as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ACET
On Friday, Adicet Bio Inc [NASDAQ:ACET] saw its stock jump 27.49% to $0.61. Over the last five days, the stock has lost -8.97%. Adicet Bio Inc shares have fallen nearly -36.60% since the year began. Nevertheless, the stocks have fallen -64.75% over the past one year. While a 52-week high of $1.73 was reached on 01/03/25, a 52-week low of $0.45 was recorded on 04/10/25. SMA at 50 days reached $0.6959, while 200 days put it at $1.0788.
Levels Of Support And Resistance For ACET Stock
The 24-hour chart illustrates a support level at 0.5226, which if violated will result in even more drops to 0.4354. On the upside, there is a resistance level at 0.6745. A further resistance level may holdings at 0.7392. The Relative Strength Index (RSI) on the 14-day chart is 48.77, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0759, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 38.19%. Stochastics %K at 21.62% indicates the stock is a holding.
